Loading
A phase 2 trial of PF-08634404, Bevacizumab, CAPOX in colorectal cancer, run by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., now recruiting.
A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients is a phase 2 interventional study registered as NCT06493760 by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., with 130 participants planned, started 2024-09-03 and due to reach its primary completion in 2025-06. Interventions recorded: SSGJ-707, Bevacizumab, Oxaliplatin, Capecitabine, Calcium Folinate. Conditions listed: Metastatic Colorectal Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares CAPOX (capecitabine, oxaliplatin), Bevacizumab, Capecitabine, Colorectal cancer.
Shares Leucovorin (folinic acid), CAPOX (capecitabine, oxaliplatin), Colorectal cancer.
Shares Leucovorin (folinic acid), CAPOX (capecitabine, oxaliplatin), Capecitabine, Colorectal cancer.
Shares PF-08634404, Colorectal cancer.
Shares Leucovorin (folinic acid), CAPOX (capecitabine, oxaliplatin), Bevacizumab.
Shares CAPOX (capecitabine, oxaliplatin), Bevacizumab, Capecitabine, Colorectal cancer.
Shares Leucovorin (folinic acid), Bevacizumab, Capecitabine.
Shares Leucovorin (folinic acid), CAPOX (capecitabine, oxaliplatin), Capecitabine.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/